NTSR2 and prostate cancer: A study on an 18F-labeled radioligand showed limited stability in vivo [65], but JMV-7488, a radiometalated NT analog targeting NTR2, demonstrated promising results in estrogen-positive breast cancer and prostate cancer animal models [33].